This Shandong pharmaceutical company is very strong! Take the 7th over-rated variety.

Pharmaceutical Network July 1st, June 29, Xinhua Pharmaceuticals announced that the company's clathromycin tablets (0.25g) through the consistency evaluationAccording to Minet.com, sales of Clamycin, a public medical institution in China, will be 1.340 billion yuan in 2019Up to now, Xinhua Pharmaceuticals has reached 7 varieties through consistency evaluation.Clamycin is a new type of large-ringest ester antibiotic made from 6-bit hydroxy-selective methylation of erythromycinCompared with erythromycin, it has stronger antibacterial activity, absorbs and distributes well, has a good inhibitory effect on a variety of aerobic and anaerobic Grameen-positive bacteria, and is mainly used to treat infectioncaused by the pathogenic bacteria sensitive to kramycin.Kramycin was developed and developed by Japan's Dazheng Pharmaceutical Co., Ltdand in 1985 authorized Abbott to develop, produce and sell in other countries except JapanTablets (size 250mg) were launched in Italy in 1990 and were later sold in more than 50 countries, including the United States, Germany and the United Kingdom.In 2019, the sales of clathromycin in the terminals of China's urban publichospitals
, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) were 1.340 billion yuan, according to MinenetAmong them, HengruiPharmaceuticalaccounted for 30.84 percent of the market share, Abbott accounted for 17 percent .　　China's public medical institutions terminal clathromycin sales (units: 10,000 yuan) with Xinhua Pharmaceuticals' kramycin tablets through consistency evaluation, the current variety of enterprises have reached 4 , respectively, Dongsun Pharmaceuticals, Modern Pharmaceuticals, Baed Pharmaceuticals, Xinhua Pharmaceuticals According to the list of the third batch of collected varieties circulated, the oral frequently released dosage form (250mg, 500mg) of kramycin is listed . carramycin tablets evaluate the of the enterprise through consistency.　　The database of consistency evaluation of the inner net shows that, so far, Xinhua Pharmaceuticals has reached seven varieties through consistency evaluation Among them, cephalosporadin capsules (0.25g), hydrochloric acid sitriquine tablets (10mg) for the first review, Catopuri tablets (25mg) for the third domestic review; . Xinhua Pharmaceuticals has evaluated the varieties.　　Source: of the Minnet database.